Welcome to our dedicated page for Abcellera Biologics news (Ticker: ABCL), a resource for investors and traders seeking the latest updates and insights on Abcellera Biologics stock.
AbCellera Biologics Inc. develops antibody-based medicines as a clinical-stage biotechnology company. Its updates center on antibody discovery and development programs in endocrinology, women’s health, immunology, oncology, and other areas, including work on complex targets such as GPCRs and ion channels.
Recurring news themes include clinical disclosures for ABCL635, an antibody therapeutic targeting NK3R for the non-hormonal treatment of moderate-to-severe vasomotor symptoms associated with menopause. Company announcements also cover financial results, earnings-call materials, investor conference participation, platform and manufacturing updates, and patent licensing or litigation-resolution developments.
AbCellera (ABCL) will present at the Cantor Global Healthcare Conference on September 9, 2026. The company will provide a live audio webcast of its presentation via a link on its Investor Relations website, with a replay accessible through the same link after the event.
AbCellera is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody-based medicines across endocrinology, women’s health, immunology, oncology, and other therapeutic areas. The company notes that its communications may include forward-looking statements subject to risks and uncertainties described in its SEC filings.
AbCellera (Nasdaq: ABCL) priced an oversubscribed underwritten public offering of 17,435,897 common shares at $9.75 per share and, in lieu of common shares to certain investors, pre-funded warrants to purchase up to 3,076,926 common shares at $9.74999 per warrant.
Gross proceeds are expected to be about $200 million before underwriting discounts, commissions and expenses. All securities are being sold by AbCellera, and the offering is expected to close on August 14, 2026, subject to customary conditions. According to AbCellera, net proceeds will fund continued R&D and clinical advancement of its internal pipeline, including lead program ABCL635, and for working capital and general corporate purposes. Jefferies, J.P. Morgan, Cantor, UBS Investment Bank and BMO Capital Markets are joint book-running managers. The securities are offered under an effective Form S-3ASR shelf registration filed on February 27, 2025.
AbCellera (Nasdaq: ABCL) has launched a proposed underwritten public offering of $200 million of its common shares and, for certain investors, pre-funded warrants to purchase common shares. All securities in the deal would be issued by AbCellera, and the offering’s completion, timing, size and final terms remain subject to market and other conditions.
According to AbCellera, net proceeds are expected to support research, development and clinical advancement of its internal pipeline, including lead clinical program ABCL635, and to provide working capital and for general corporate purposes. Jefferies, J.P. Morgan, Cantor, UBS Investment Bank and BMO Capital Markets are acting as joint book-running managers. The securities are being offered under an effective Form S-3ASR shelf registration filed with the SEC on February 27, 2025. No securities are being offered or sold in Canada or to Canadian residents.
AbCellera (Nasdaq: ABCL) reported positive top-line results from the Phase 2 portion of its Phase 1/2 trial of ABCL635, an investigational NK3 receptor antibody for moderate-to-severe menopausal vasomotor symptoms. A single 600 mg subcutaneous dose met primary endpoints, producing statistically significant reductions in hot flash frequency and severity at week 4 versus placebo.
According to AbCellera, ABCL635 reduced daily moderate-to-severe events by a mean 8.8 versus 3.5 for placebo (placebo-adjusted difference 5.3; p<0.001) and achieved an 83% vs 33% mean percent reduction in frequency. Severity scores fell by 1.4 vs 0.3 (difference 1.1; p<0.001), corresponding to a 58% vs 12% mean percent reduction. Improvements in sleep and patient global impression of change were also observed. ABCL635 was well tolerated over four weeks, with no serious or severe adverse events or discontinuations; the most common treatment-emergent events were headache, fatigue, and injection site reaction.
AbCellera (Nasdaq: ABCL) plans to release top-line results from its Phase 2 trial of ABCL635 for treating moderate-to-severe vasomotor symptoms (VMS) due to menopause before the market opens on Monday, August 10, 2026. Management will host an investor conference call at 4:30 a.m. PT (7:30 a.m. ET), with a live audio webcast and replay accessible via AbCellera’s Investor Relations website.
ABCL635 is a potential first-in-class, non-hormonal antibody therapy that targets NK3R, a clinically validated GPCR expressed on KNDy neurons. The ongoing Phase 2 study (NCT07118891) is a multicenter, randomized, double-blind, placebo-controlled trial in approximately 80 postmenopausal women evaluating reduction in VMS frequency and severity.
AbCellera (Nasdaq: ABCL) reported Q2 2026 revenue of $4.1 million, down from $17.1 million in Q2 2025, and a net loss of $55.4 million, or $(0.18) per share, versus a $34.7 million loss a year earlier. R&D expenses rose to $46.0 million, while SG&A decreased to $13.9 million.
According to AbCellera, it ended the quarter with over $565 million in cash and marketable securities and total available liquidity above $675 million, including $110 million in non-dilutive government funding. The company signed a Jazz collaboration with $84 million in upfront payments and potential milestones up to $792 million per program, and a Vertex collaboration with $28 million upfront. AbCellera expects Phase 2 top-line data for ABCL635 in August 2026 and Phase 1 top-line data for ABCL575 in Q4 2026.
AbCellera (Nasdaq: ABCL) announced a collaboration with Vertex Pharmaceuticals (Nasdaq: VRTX) to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. AbCellera will use its proprietary TCE platform to lead discovery and early development activities, while Vertex will fund all research and development costs and hold the rights to develop and commercialize resulting multispecific antibodies.
According to AbCellera, it will receive $28 million in total upfront payments and may earn additional preclinical, development, regulatory, and commercial milestone payments, plus tiered royalties on net sales. The companies may also mutually agree for AbCellera to conduct cell line development, process development, and clinical manufacturing through Phase 1 for collaboration programs.
AbCellera (Nasdaq: ABCL) will report its second quarter 2026 financial results on Wednesday, August 5, 2026. The company will host an earnings conference call at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time), with a live audio webcast and replay available on its Investor Relations website.
AbCellera (Nasdaq: ABCL) appointed Lynn Seely, M.D. to its Board of Directors as an independent director.
Dr. Seely is president and CEO of Lyell Immunopharma and brings extensive strategic, clinical, and commercial experience in endocrinology, oncology, and women’s health, including leadership roles at Myovant Sciences, Medivation, and Blueprint Medicines.
AbCellera (Nasdaq: ABCL) and Jazz Pharmaceuticals announced a preclinical collaboration, option and license agreement to discover next-generation T-cell engaging multispecific antibodies for gastrointestinal cancers and other solid tumors.
AbCellera receives $56 million upfront, up to $28 million for a third program, and may earn up to $792 million per program in potential option, development, regulatory and commercial milestone payments, plus tiered royalties on net sales.